Cambridge, MA (U.S.) and Lyon (France), May 24, 2022 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic ...
PARIS, FRANCE/ ACCESSWIRE / May 16, 2023 / Akkadian Partners SA ("Akkadian") has announced that Akkadian Partners Fund, a Luxemburg registered securitisation fund under its management, now holds over ...
In relation with the announced merger of PHERECYDES into ERYTECH (the “Proposed Merger”), ERYTECH and PHERECYDES entered into a merger agreement on May 15, 2023, pursuant to which PHERECYDES will be ...
LYON, France and CAMBRIDGE, Mass., June 09, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP),a clinical-stage biopharmaceutical company developing innovative therapies by ...
U.S. cell therapy manufacturing facility sold to Catalent for a total consideration of USD 44.5 million Following the disappointing results of the Company’s Phase 3 trial in pancreatic cancer, ERYTECH ...
Akkadian’s challenge of the merger is based on incomplete information and misleading arguments Akkadian has not presented any valuable alternative option Akkadian’s unfounded actions present a risk of ...
Merger approved with large majority by the shareholders of both companies New governance structure implemented Ambition to create a global leader in extended phage therapies to target antimicrobial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results